Abstract 1151P
Background
A substantial increase in melanoma (MM) incidence has been consistently observed worldwide over the past decades. MM mortality rates, however, remained stable or declined over the past years in most countries. Given the paucity of MM mortality data in Brazil, we sought to characterize MM mortality trends in southeastern Brazil and its relationship with demographic variables.
Methods
A cross-sectional registry-based analysis was conducted to describe MM mortality trends in the State of Sao Paulo (Brazil) from 1996 to 2016. Melanoma-related death records, including gender and age were collected from SEADE Foundation’s database, an official entity charged with generating statistical data for the State of Sao Paulo. The annual percentage change (APC) was calculated to identify mortality trends over the period. Trend analysis was carried out by linear regression and an increase or decrease in trend was considered statistically significant when p-value < 0.05.
Results
From 1996 to 2016, 8217 deaths from melanoma were recorded in the State of São Paulo, Brazil. Average annual mortality due to melanoma was 1.05/100,000 (1.17/100,000 for males and 0.93/100,000 for females). Male mortality from melanoma exceeded female rates throughout the period since 1999. An increasing MM mortality trend was detected among males, regardless of age (APC 1.72%, p < 0.001), and was more pronounced for the for males older than 60 years (APC 2.63%, p < 0.001). MM mortality rates have also increased for the age group older than 60 years (APC 1.11%, p < 0.001), regardless of gender. A non-statistically significant increase in the overall MM mortality rate was observed over the 20-year period analyzed (APC 0.36%, p = 0.4).
Conclusions
Our data suggest a stable MM mortality over the last two decades for the general population. However, a significant increase in MM mortality rates has been demonstrated among males and in the population over 60 years old.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP - Sao Paulo State Research Foundation.
Disclosure
G. Nader Marta: Travel/Accommodation/Expenses: Bayer; Travel/Accommodation/Expenses: Roche. R. Ramella Munhoz: Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Merck Sharp Dohme; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Roche. O. Feher: Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche. All other authors have declared no conflicts of interest.